Omadacycline

Paratek Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference 2021

Retrieved on: 
Tuesday, August 3, 2021

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use, today announced that Adam Woodrow, President and Chief Commercial Officer, will participate in a panel discussion at the Wedbush PacGrow Healthcare Conference 2021.

Key Points: 
  • BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use, today announced that Adam Woodrow, President and Chief Commercial Officer, will participate in a panel discussion at the Wedbush PacGrow Healthcare Conference 2021.
  • The discussion will take place on August 11, 2021 at 4:40 p.m. E.T.
  • Paratek Pharmaceuticals, Inc.is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use.
  • Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Monday, August 2, 2021

These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.

Key Points: 
  • These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.
  • Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.
  • Paratek is also conducting a Phase 2b Study in a rare disease, Nontuberculous Mycobacterial (NTM) Pulmonary Disease, caused by Mycobacterium abscessus Complex (MABc) with NUZYRA.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021

Retrieved on: 
Monday, August 2, 2021

Domestic investors wishing to participate in the call should dial: 855-327-6837 and international investors should dial: 631-891-4304.

Key Points: 
  • Domestic investors wishing to participate in the call should dial: 855-327-6837 and international investors should dial: 631-891-4304.
  • Paratek Pharmaceuticals, Inc.is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use.
  • Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.
  • Paratek is also conducting a Phase 2b Study in a rare disease, Nontuberculous Mycobacterial (NTM) Pulmonary Disease, caused by Mycobacterium abscessus Complex (MABc) with NUZYRA.

Paratek Pharmaceuticals Hosting Investor Webinar with Corporate Updates and Key Opinion Leader and Patient Advocate Presentations on Non-Tuberculous Mycobacteria, M. abscessus

Retrieved on: 
Thursday, June 10, 2021

During the webinar, Paratek will provide a corporate overview and an update on NUZYRA (omadacycline), the companysonce-daily oral and intravenous antibiotic and discuss future development opportunities.

Key Points: 
  • During the webinar, Paratek will provide a corporate overview and an update on NUZYRA (omadacycline), the companysonce-daily oral and intravenous antibiotic and discuss future development opportunities.
  • His Center for Infectious Disease Studies has served as the lead institution and coordinating center for multiple cohort studies and clinical trials.
  • As the public face of the organization, she presents regularly at conferences on a variety of subjects including patient engagement and original patient preference research.
  • Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, June 1, 2021

Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Key Points: 
  • Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.
  • Absorption of tetracyclines, including NUZYRA is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations.
  • To report SUSPECTED ADVERSE REACTIONS, contact Paratek Pharmaceuticals, Inc. at 1-833-727-2835 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

Retrieved on: 
Tuesday, June 1, 2021

The approval of an oral-only dose regimen for NUZYRA in pneumonia represents a significant opportunity to offer clinicians the ability to treat patients in either the outpatient or primary care setting.

Key Points: 
  • The approval of an oral-only dose regimen for NUZYRA in pneumonia represents a significant opportunity to offer clinicians the ability to treat patients in either the outpatient or primary care setting.
  • The availability of an oral-only dosing regimen of NUZYRA in pneumonia helps address a significant gap for an effective, safe and well-tolerated oral antibiotic in the primary care setting.
  • The Companys lead commercial product, NUZYRA (omadacycline), is an oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
  • NUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous (IV) formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

Paratek Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 26, 2021

BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use, today announced that the Company will present at the Jefferies Virtual Healthcare Conference which will be broadcast on Wednesday, June 2, 2021 at 9:00 a.m.

Key Points: 
  • BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use, today announced that the Company will present at the Jefferies Virtual Healthcare Conference which will be broadcast on Wednesday, June 2, 2021 at 9:00 a.m.
  • Paratek Pharmaceuticals, Inc.is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use.
  • Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

Paratek Pharmaceuticals Announces First Quarter 2021 Total Revenue of $16.4 Million and Initiation of First BARDA Procurement

Retrieved on: 
Monday, May 17, 2021

We continued to see quarter over quarter growth with NUZYRA, which generated $13.2 million in net sales in the first quarter, reflecting the health of our commercial business,\xe2\x80\x9d said Evan Loh, M.D., Chief Executive Officer at Paratek.

Key Points: 
  • We continued to see quarter over quarter growth with NUZYRA, which generated $13.2 million in net sales in the first quarter, reflecting the health of our commercial business,\xe2\x80\x9d said Evan Loh, M.D., Chief Executive Officer at Paratek.
  • \xe2\x80\x9cWe believe that 2021 will be a transformative year for Paratek.
  • We are excited to announce that BARDA has now initiated the first procurement of NUZYRA valued at ~$38 million.
  • Paratek intends to use this website as a means of disclosing material, non-public information and for complying with its disclosure obligations under Regulation FD.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Monday, May 3, 2021

b"BOSTON, May 03, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and\xc2\xa0military use, today announced that on April 30, 2021, the Company granted stock options to seven new employees of the Company.

Key Points: 
  • b"BOSTON, May 03, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and\xc2\xa0military use, today announced that on April 30, 2021, the Company granted stock options to seven new employees of the Company.
  • Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.\nParatek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA\xc2\xae (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC, or Almirall.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.\nIn 2019, Paratek was awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of NUZYRA for the treatment of pulmonary anthrax.\nFor more information, visit www.ParatekPharma.com or follow @ParatekPharma on Twitter.\nNUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
  • A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains.\nFor more information, visit www.ParatekPharma.com or follow @ParatekPharma\xc2\xa0on Twitter.\n"

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, April 1, 2021

These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.

Key Points: 
  • These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.
  • Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.
  • In 2019, Paratek was awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of NUZYRA for the treatment of pulmonary anthrax.